イミキモド
参考資料

↑  Drugs.com Drugs.com international listings for imiquimod Page accessed June 14, 2015
1 2  “Imiquimod topical Use During Pregnancy”. Drugs.com (29 May 2019). 14 July 2020閲覧。
↑  “Imiquimod Topical” (英語). MedlinePlus.  National Library of Medicine. 2 June 2021閲覧。
1 2 3  “ベセルナクリーム5％ 添付文書”. www.info.pmda.go.jp.   PMDA. 2021年6月20日閲覧。
↑  'Imiquimod should be used for treatment of [superficial basal cell carcinoma] only when surgery is medically less appropriate ... .' USA Food And Drug Administration, 'FDA Approval for Imiquimod', , current at 2011-Jan-1, accessed 2012-Oct-19
↑  American Cancer Society, Guide To Cancer Drugs,  (accessed 2014-Apr-28)
1 2 3  European Medicines Agency. First published Sept 14,2009, updated March 25, 2015. EMA Summary of Product Characteristics
1 2 3 4  “Aldara EPAR”. European Medicines Agency (EMA). 14 July 2020閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
1 2  “Zyclara EPAR”. European Medicines Agency (EMA). 14 July 2020閲覧。 Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑  PDR Health PDR: Aldara
↑  Schön, M.P; Schön, M (2007). “Imiquimod: Mode of action”. British Journal of Dermatology 157:  8–13. doi:10.1111/j.1365-2133.2007.08265.x. PMID 18067624.
↑  Walter, Anne; Schäfer, Matthias; Cecconi, Virginia; Matter, Claudia; Urosevic-Maiwald, Mirjana; Belloni, Benedetta; Schönewolf, Nicola; Dummer, Reinhard et al. (2013). “Aldara activates TLR7-independent immune defence”. Nature Communications 4:  1560. Bibcode: 2013NatCo...4.1560W. doi:10.1038/ncomms2566. PMID 23463003.
↑  Hemmi, Hiroaki; Kaisho, Tsuneyasu; Takeuchi, Osamu; Sato, Shintaro; Sanjo, Hideki; Hoshino, Katsuaki; Horiuchi, Takao; Tomizawa, Hideyuki et al. (2002). “Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway”. Nature Immunology 3 (2):  196–200. doi:10.1038/ni758. PMID 11812998.
↑  Sauder, D.N. (2003). “Imiquimod: Modes of action”. British Journal of Dermatology 149:  5–8. doi:10.1046/j.0366-077x.2003.05628.x. PMID 14616337.
1 2  Miller, R.L; Gerster, J.F; Owens, M.L; Slade, H.B; Tomai, M.a (1999). “Review Article Imiquimod applied topically: A novel immune response modifier and new class of drug”. International Journal of Immunopharmacology 21 (1):  1–14. doi:10.1016/s0192-0561(98)00068-x. PMID 10411278.
↑  “Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function”. Exp. Biol. Med. (Maywood) 233 (8):  968–79. (August 2008). doi:10.3181/0802-RM-58. PMID 18480416.
↑  Randall L. Halcomb. TLR-7 Agonists for the Treatment of Viral Hepatitis. Chapter 10 in Successful Strategies for the Discovery of Antiviral Drugs. Issue 32 of RSC drug discovery series. Eds Manoj C. Desai and Nicholas A. Meanwell. Royal Society of Chemistry, 2013. ISBN 9781849736572
↑  Centerwatch. Centerwatch:Aldara (imiquimod) Page accessed June 14, 2015
↑  National Cancer Institute. Updated: July 3, 2013 NCI: FDA Approval for Imiquimod
↑  “ベセルナクリーム5％ インタビューフォーム”.   PMDA. 2021年6月21日閲覧。
↑  “Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts - Study Results - ClinicalTrials.gov”. clinicaltrials.gov. 2021年6月21日閲覧。
↑  “Aldara (imiquimod) cream for topical use. Prescribing information.”. 2013年11月2日時点のオリジナルよりアーカイブ。2021年6月21日閲覧。
↑  Molluscum Contagiosum~treatment - eMedicine
↑  Theos, A. U.; Cummins, R; Silverberg, N. B.; Paller, A. S. (2004). “Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial”. Cutis 74 (2):  134–8, 141–2. PMID 15379366.
↑  Bayerl, C; Feller, G; Goerdt, S (2003). “Experience in treating molluscum contagiosum in children with imiquimod 5% cream”. The British Journal of Dermatology 149 Suppl 66:  25–9. doi:10.1046/j.0366-077x.2003.05631.x. PMID 14616342.
↑  Arican, Ozer (2006). “Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children”. Pediatrics International 48 (4):  403–5. doi:10.1111/j.1442-200X.2006.02229.x. PMID 16911087.
↑  Van Seters, Manon; Van Beurden, Marc; Ten Kate, Fiebo J.W.; Beckmann, Ilse; Ewing, Patricia C.; Eijkemans, Marinus J.C.; Kagie, Marjolein J.; Meijer, Chris J.M. et al. (2008). “Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod”. New England Journal of Medicine 358 (14):  1465–73. doi:10.1056/NEJMoa072685. PMID 18385498.
↑  Buck, Henry W.; Guth, Kathy J. (2003). “Treatment of Vaginal Intraepithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream”. Journal of Lower Genital Tract Disease 7 (4):  290–3. doi:10.1097/00128360-200310000-00011. PMID 17051086.
↑  Kwok, Chun Shing; Gibbs, Sam; Bennett, Cathy; Holland, Richard; Abbott, Rachel (2012). “Topical treatments for cutaneous warts”. Cochrane Database of Systematic Reviews (9):  CD001781. doi:10.1002/14651858.CD001781.pub3. PMC 8101088. PMID 22972052. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101088/.
1 2 3 4  “Imiquimod for non-genital cutaneous warts”. www.dpic.org. 2021年6月21日閲覧。
↑  Harwood, C.A.; Perrett, C.M.; Brown, V.L.; Leigh, I.M.; Mcgregor, J.M.; Proby, C.M. (2005). “Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals”. British Journal of Dermatology 152 (1):  122–129. doi:10.1111/j.1365-2133.2005.06322.x. PMID 15656812. https://www.medscape.com/viewarticle/498455_2.
↑  Ahn, Christine S.; Huang, William W. (2014). “Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review”. American Journal of Clinical Dermatology 15 (5):  387–99. doi:10.1007/s40257-014-0093-5. PMID 25186654.
Imiquimod 1H NMR spectrum